BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 17577104)

  • 21. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
    Fujisawa M; Yorikane R; Matsuoka Y; Koike H; Ueno K
    J Cardiovasc Pharmacol; 2013 Jan; 61(1):63-9. PubMed ID: 23288106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension.
    Kishi T; Hirooka Y; Konno S; Sunagawa K
    Clin Exp Hypertens; 2009 May; 31(3):241-9. PubMed ID: 19387900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
    Nakamoto M; Ohya Y; Sakima A; Yamazato M; Takishita S
    Hypertens Res; 2007 Apr; 30(4):359-66. PubMed ID: 17541215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
    Fukao K; Shimada K; Hiki M; Kiyanagi T; Hirose K; Kume A; Ohsaka H; Matsumori R; Kurata T; Miyazaki T; Daida H
    Cardiovasc Diabetol; 2011 Sep; 10():79. PubMed ID: 21906391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction.
    Zaliƫnas R; Brazdzionyte J; Zabiela V; Jurkevicius R
    Int J Cardiol; 2005 Jun; 101(3):347-53. PubMed ID: 15907400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
    Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
    Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
    Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K
    Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
    Takami T; Saito Y
    Vasc Health Risk Manag; 2011; 7():383-90. PubMed ID: 21796252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
    Ando K; Haneda M; Ito S; Kashihara N; Node K; Nangaku M; Shimosawa T; Kishimoto J; Fujita T
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
    Ito H; Ishii K; Iwakura K; Nakamura F; Nagano T; Takiuchi S
    Hypertens Res; 2009 Oct; 32(10):895-900. PubMed ID: 19680260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
    Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
    Kondo T; Goto R; Sonoda K; Yasuda T; Ono K; Takaki Y; Yatsuda R; Miyamura N; Araki E
    Intern Med; 2010; 49(7):637-43. PubMed ID: 20371952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
    Nada T; Nomura M; Koshiba K; Kawano T; Mikawa J; Ito S
    Arzneimittelforschung; 2007; 57(11):698-704. PubMed ID: 18193691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).
    Kojima T; Miyauchi K; Yokoyama T; Yokoyama K; Kurata T; Suwa S; Kawamura M; Tamura H; Okazaki S; Inoue K; Fujiwara Y; Sumiyoshi M; Tanimoto K; Nakazato Y; Yamagami S; Hiro T; Komiyama N; Daida H
    Circ J; 2011; 75(5):1071-9. PubMed ID: 21471671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
    Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure.
    Hoshide S; Kario K; Ishikawa J; Eguchi K; Shimada K
    Hypertens Res; 2005 Dec; 28(12):1003-8. PubMed ID: 16671340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.